Cargando…

How I Manage Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL), is a hematologic malignancy characterized by the uncontrolled proliferation of mature B lymphocytes. CLL is the most prevalent leukemia in Western countries. Its presentation can range from asymptomatic with the incidental finding of absolute lymphocytosis on a ro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nasnas, Patrice, Cerchione, Claudio, Musuraca, Gerardo, Martinelli, Giovanni, Ferrajoli, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443285/ https://www.ncbi.nlm.nih.gov/pubmed/37606492 http://dx.doi.org/10.3390/hematolrep15030047

Ejemplares similares

A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia
por: Martino, Massimo, et al.
Publicado: (2021)

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
por: Bravaccini, Sara, et al.
Publicado: (2020)

Chronic Lymphocytic Leukemia
por: Vaisitti, Tiziana, et al.
Publicado: (2020)

Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies
por: Rivera, Daniel, et al.
Publicado: (2022)

How I manage frontline transplant-eligible multiple myeloma in Italy
por: Montefusco, Vittorio, et al.
Publicado: (2020)

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
por: Gottardi, Michele, et al.
Publicado: (2021)

How I manage frontline transplant-ineligible multiple myeloma
por: Derudas, Daniele, et al.
Publicado: (2020)

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
por: Vitale, Candida, et al.
Publicado: (2021)

Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia
por: Khan, Maliha, et al.
Publicado: (2017)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review
por: Autore, Francesco, et al.
Publicado: (2018)

BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia
por: Falchi, Lorenzo, et al.
Publicado: (2016)

Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report
por: Cerchione, Claudio, et al.
Publicado: (2020)

Treatment free remission in chronic myeloid leukemia: Lights and shadows
por: Molica, Matteo, et al.
Publicado: (2020)

Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients
por: De Matteis, Serena, et al.
Publicado: (2018)

The Role of Monoclonal Antibodies in the Management of Leukemia
por: Al-Ameri, Ali, et al.
Publicado: (2010)

Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab
por: Jain, Punit, et al.
Publicado: (2016)

Update in the management of chronic lymphocytic leukemia
por: Maddocks, Kami J, et al.
Publicado: (2009)

Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
por: Savoy, J. Michael, et al.
Publicado: (2018)

The molecular pathogenesis of multiple myeloma
por: Bolli, Niccolò, et al.
Publicado: (2020)

Precision Medicine Management of Chronic Lymphocytic Leukemia
por: Moia, Riccardo, et al.
Publicado: (2020)

How I treat relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2020)

Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon
por: Martino, Massimo, et al.
Publicado: (2022)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
por: Cerchione, Claudio, et al.
Publicado: (2021)

Management of relapsed/refractory Chronic Lymphocytic Leukemia
por: Woyach, Jennifer A.
Publicado: (2022)

PB2263: SUPPORTIVE CARE IN LOW-RISK MYELODYSPLASTIC SYNDROMES: ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS)
por: Cerchione, C., et al.
Publicado: (2022)

New emerging therapies in the management of chronic lymphocytic leukemia
por: Li, Xiao-Lin, et al.
Publicado: (2016)

Pharmacists’ Role in Managing Patients with Chronic Lymphocytic Leukemia
por: Chen, Kevin Y., et al.
Publicado: (2020)

Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
por: Sood, Nitin, et al.
Publicado: (2021)

The spectrum of use of rituximab in chronic lymphocytic leukemia
por: Tedeschi, Alessandra, et al.
Publicado: (2010)

Pegfilgrastim in Supportive Care of Hodgkin Lymphoma
por: Cerchione, Claudio, et al.
Publicado: (2022)

STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells
por: Rozovski, Uri, et al.
Publicado: (2018)

STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells
por: Rozovski, Uri, et al.
Publicado: (2021)

Fludarabine in the treatment of chronic lymphocytic leukemia: a review
por: Ricci, Francesca, et al.
Publicado: (2009)

Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
por: D'Arena, Giovanni, et al.
Publicado: (2013)

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab
por: Laurenti, Luca, et al.
Publicado: (2016)

The BET Inhibitor GS-5829 Targets Chronic Lymphocytic Leukemia Cells and Their Supportive Microenvironment
por: Kim, Ekaterina, et al.
Publicado: (2019)

Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
por: Waggoner, Matthew, et al.
Publicado: (2022)

How I diagnose and treat chronic myelomonocytic leukemia
por: Patnaik, Mrinal M.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_81pa2gha8dsgmtni10o2p89ij7